Inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis are idiopathic, chronic relapsing autoimmune disorders of the small intestine and colon that affect over 5 million people worldwide. Treatment of IBD is complicated by the heterogenous presentation and development of disease symptoms. Dozens of drug discovery and development programs target multiple pathways in IBD and employ rodent models, which demonstrate common clinical and histopathological features of IBD. Nevertheless, the models differ in how they are generated and display distinct phenotypic characteristics. A major limitation of such models is the unknown status of underlying protein networks and pathways driving disease pathology and therapeutic response. This problem complicates both model selection and the interpretation of study results.
To help solve the problem, Inotiv employs new proteome analysis technology to comprehensively characterize the protein pathways of IBD models. Inotiv tissue proteome analyses reveal the systems level actions of therapeutics and provides critical new data to bridge preclinical pharmacology studies to human disease.
Complete the form to get your copy today!
